JP2021512087A5 - - Google Patents

Info

Publication number
JP2021512087A5
JP2021512087A5 JP2020541535A JP2020541535A JP2021512087A5 JP 2021512087 A5 JP2021512087 A5 JP 2021512087A5 JP 2020541535 A JP2020541535 A JP 2020541535A JP 2020541535 A JP2020541535 A JP 2020541535A JP 2021512087 A5 JP2021512087 A5 JP 2021512087A5
Authority
JP
Japan
Prior art keywords
egfr
alkyl
independently
halogen
monosubstituted
Prior art date
Application number
JP2020541535A
Other languages
English (en)
Japanese (ja)
Other versions
JPWO2019149164A5 (https=
JP2021512087A (ja
JP7427597B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/CN2019/073355 external-priority patent/WO2019149164A1/en
Publication of JP2021512087A publication Critical patent/JP2021512087A/ja
Publication of JP2021512087A5 publication Critical patent/JP2021512087A5/ja
Publication of JPWO2019149164A5 publication Critical patent/JPWO2019149164A5/ja
Priority to JP2023180451A priority Critical patent/JP7738619B2/ja
Application granted granted Critical
Publication of JP7427597B2 publication Critical patent/JP7427597B2/ja
Priority to JP2025145276A priority patent/JP2025179139A/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2020541535A 2018-01-31 2019-01-28 Ｅｒｂｂ／ｂｔｋ阻害剤 Active JP7427597B2 (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2023180451A JP7738619B2 (ja) 2018-01-31 2023-10-19 Ｅｒｂｂ／ｂｔｋ阻害剤
JP2025145276A JP2025179139A (ja) 2018-01-31 2025-09-02 Ｅｒｂｂ／ｂｔｋ阻害剤

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
CNPCT/CN2018/074791 2018-01-31
CN2018074791 2018-01-31
CN2018118569 2018-11-30
CNPCT/CN2018/118569 2018-11-30
PCT/CN2019/073355 WO2019149164A1 (en) 2018-01-31 2019-01-28 Erbb/btk inhibitors

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2023180451A Division JP7738619B2 (ja) 2018-01-31 2023-10-19 Ｅｒｂｂ／ｂｔｋ阻害剤

Publications (4)

Publication Number Publication Date
JP2021512087A JP2021512087A (ja) 2021-05-13
JP2021512087A5 true JP2021512087A5 (https=) 2022-02-02
JPWO2019149164A5 JPWO2019149164A5 (https=) 2022-02-02
JP7427597B2 JP7427597B2 (ja) 2024-02-05

Family

ID=67478612

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2020541535A Active JP7427597B2 (ja) 2018-01-31 2019-01-28 Ｅｒｂｂ／ｂｔｋ阻害剤
JP2023180451A Active JP7738619B2 (ja) 2018-01-31 2023-10-19 Ｅｒｂｂ／ｂｔｋ阻害剤
JP2025145276A Pending JP2025179139A (ja) 2018-01-31 2025-09-02 Ｅｒｂｂ／ｂｔｋ阻害剤

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2023180451A Active JP7738619B2 (ja) 2018-01-31 2023-10-19 Ｅｒｂｂ／ｂｔｋ阻害剤
JP2025145276A Pending JP2025179139A (ja) 2018-01-31 2025-09-02 Ｅｒｂｂ／ｂｔｋ阻害剤

Country Status (14)

Country Link
US (2) US11007198B2 (https=)
EP (2) EP4356975A3 (https=)
JP (3) JP7427597B2 (https=)
KR (2) KR20250046340A (https=)
CN (3) CN111587244A (https=)
AU (2) AU2019215538B2 (https=)
CA (1) CA3086616A1 (https=)
DK (1) DK3746424T3 (https=)
ES (1) ES2977484T3 (https=)
MX (2) MX2020007947A (https=)
PT (1) PT3746424T (https=)
RU (2) RU2764069C1 (https=)
TW (1) TWI798334B (https=)
WO (1) WO2019149164A1 (https=)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11896597B2 (en) * 2018-01-31 2024-02-13 Dizal (Jiangsu) Pharmaceutical Co., Ltd. ErbB/BTK inhibitors
TWI798334B (zh) * 2018-01-31 2023-04-11 大陸商迪哲（江蘇）醫藥股份有限公司 Ｅｒｂｂ／ｂｔｋ抑制劑
US12157730B2 (en) 2019-03-19 2024-12-03 Voronoi Inc. Heteroaryl derivative, method for producing same, and pharmaceutical composition comprising same as effective component
AU2020240382B2 (en) 2019-03-19 2022-08-25 Voronoi Inc. Heteroaryl derivative, method for producing same, and pharmaceutical composition comprising same as effective component
WO2021104305A1 (zh) * 2019-11-26 2021-06-03 上海翰森生物医药科技有限公司 含氮多环类衍生物抑制剂、其制备方法和应用
CN111057021B (zh) * 2019-12-11 2023-05-23 中国药科大学 均三嗪类化合物及其制备方法和用途
US20230137932A1 (en) * 2020-01-07 2023-05-04 Dana-Farber Cancer Institute, Inc. Cyano-pyrimidine inhibitors of egfr/her2
CN111470998B (zh) * 2020-06-28 2020-09-25 上海皓元生物医药科技有限公司 用于合成喜树碱衍生物的中间体及其制备方法和用途
CN112409281B (zh) * 2020-08-20 2022-11-18 上海大学 (e)-3-(3-氯-2-氟-6-(1h-四氮唑-1-基)苯基)丙烯酸的合成方法
CN112679446A (zh) * 2020-10-26 2021-04-20 都创(上海)医药科技有限公司 一种合成反式-3-(3-氯-2-氟-6-(1h-四氮唑-1-基)苯基)丙烯酸的方法
WO2022206797A1 (zh) * 2021-03-30 2022-10-06 贝达药业股份有限公司 Egfr抑制剂及其组合物和用途
EP4323356A1 (en) 2021-04-13 2024-02-21 Nuvalent, Inc. Amino-substituted heterocycles for treating cancers with egfr mutations
AU2022303386A1 (en) * 2021-07-02 2023-12-14 Aldeyra Therapeutics, Inc. Heterocyclic aldehyde trapping compounds and uses thereof
EP4380924A4 (en) * 2021-08-02 2025-10-01 Dizal Jiangsu Pharmaceutical Co Ltd NEW PHARMACEUTICAL SALTS AND POLYMORPHIC FORMS OF AN ERBB AND BTK INHIBITOR
CN115181093B (zh) * 2022-08-01 2023-04-25 重庆医科大学 Sunvozertinib中间体的制备方法
WO2024261740A1 (en) 2023-06-23 2024-12-26 Assia Chemical Industries, Ltd. Solid state forms of sunvozertinib
WO2025247783A1 (en) 2024-05-29 2025-12-04 Syngenta Crop Protection Ag Pesticidally active dihydro-benzoxazinone compounds

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1719762B1 (en) * 2004-02-27 2012-06-27 Eisai R&D Management Co., Ltd. Novel pyridine derivative and pyrimidine derivative (1)
US8338439B2 (en) 2008-06-27 2012-12-25 Celgene Avilomics Research, Inc. 2,4-disubstituted pyrimidines useful as kinase inhibitors
TWI546290B (zh) * 2008-06-27 2016-08-21 賽基艾維洛米斯研究股份有限公司 雜芳基化合物及其用途
PL2805940T3 (pl) 2012-01-17 2017-06-30 Astellas Pharma Inc. Związek pirazynokarboksyamidowy
PL2825042T3 (pl) * 2012-03-15 2019-02-28 Celgene Car Llc Sole inhibitora kinazy receptora czynnika wzrostu naskórka
US20150166591A1 (en) * 2012-05-05 2015-06-18 Ariad Pharmaceuticals, Inc. Methods and compositions for raf kinase mediated diseases
BR112015010221B1 (pt) 2012-11-06 2022-09-13 Shanghai Fochon Pharmaceutical Co., Ltd. Inibidores de quinase alk, seus usos, composição farmacêutica, e método para fabricação de medicamento
SG11201600055PA (en) * 2013-07-11 2016-02-26 Betta Pharmaceuticals Co Ltd Protein tyrosine kinase modulators and methods of use
CN105377835B (zh) * 2013-07-11 2018-08-17 贝达药业股份有限公司 酪氨酸蛋白激酶调节剂及其应用方法
US9415050B2 (en) 2013-08-12 2016-08-16 Pharmacyclics Llc Methods for the treatment of HER2 amplified cancer
CN105384694B (zh) * 2014-08-22 2020-09-04 四川海思科制药有限公司 一种取代的氨基嘧啶衍生物及其制备方法和药物用途
CN106883213B (zh) * 2015-12-15 2021-04-20 合肥中科普瑞昇生物医药科技有限公司 一种egfr和alk激酶的双重抑制剂
CN106905245B (zh) * 2015-12-23 2021-06-25 正大天晴药业集团股份有限公司 2,4-二取代的嘧啶类化合物
CN106928150B (zh) * 2015-12-31 2020-07-31 恩瑞生物医药科技（上海）有限公司 丙烯酰胺苯胺衍生物及其药学上的应用
CN106083736A (zh) * 2016-06-21 2016-11-09 郑州泰基鸿诺医药股份有限公司 一种嘧啶类化合物、egfr抑制剂及其应用
TWI798334B (zh) * 2018-01-31 2023-04-11 大陸商迪哲（江蘇）醫藥股份有限公司 Ｅｒｂｂ／ｂｔｋ抑制劑
KR102782739B1 (ko) * 2018-03-13 2025-03-20 보로노이 주식회사 2,4,5-치환된 피리미딘 유도체, 이의 제조방법 및 이를 유효성분으로 포함하는 암의 예방 또는 치료용 약학적 조성물

Similar Documents

Publication Publication Date Title
JP2021512087A5 (https=)
CN109789146B (zh) 趋化因子受体调节剂及其用途
IL268030B2 (en) Bicyclics as allosteric shp2 inhibitors
JPWO2019149164A5 (https=)
JP2015508103A5 (https=)
JP2019031560A5 (https=)
JP2018517686A5 (https=)
JP2019500352A5 (https=)
JP2021523159A5 (https=)
JP2020506951A5 (https=)
MX2022013054A (es) Derivados de imidazolidinona y uso medico de los mismos.
JP2016513661A5 (https=)
JP2013010792A5 (https=)
JP2020502268A5 (https=)
RU2015143542A (ru) Ингибиторы jak2 и alk2 и способы их использования
JP2016506916A5 (https=)
JP2014501766A5 (https=)
JP2008509949A5 (https=)
JP2019535723A5 (https=)
CN111918652A (zh) 用于治疗eb病毒阳性的癌症的趋化因子受体调节剂
JP2018513832A5 (https=)
RU2016134751A (ru) Соединения
JP2015502367A5 (https=)
JP2020128426A5 (https=)
JPWO2019214634A5 (https=)